Abstract
Transdermal patches are innovative drug delivery systems and can be used for achieving efficient systemic effect by passing hepatic first-pass metabolism and increasing the fraction absorbed. The transdermal therapeutic system provide for continuous drug release through intact skin into the systemic blood stream during a prolong time at a preset rate. Desloratadine, on oral administration, may cause many adverse effects such as headache, fatigue, dryness of mouth, nose or throat, nausea, vomiting, drowsiness etc. and it is also poorly water soluble, so it shows dissolution rate limited absorption. To avoid these problems, the matrix type transdermal patches of Desloratadine are prepared by solvent casting technique on mercury substrate. For this purpose transdermal patches were prepared by using film-forming polymer such as HPMC 6 cps with PG as a plasticzer by solvent evaporation technique. The patches produced were found to be satisfactory in terms of physicochemical properties like appearance, thickness, weight variation, folding endurance, moisture content, tensile strength, percent elongation at break and percent drug content. Prepared patches exhibited zero order kinetics permeation of the drug from the patches was governed by a diffusion mechanism. Drug-excipient interaction studies will be carried out using FTIR technique. The optimized batch (F7- HPMC 6 cps 6% and PG 3%) was subjected to stability studies for a period of 1 month. The results indicated that there was no appreciable change in the values of in vitro diffusion profile.
Highlights
Transdermal drug delivery systems are formulations that are applied to the body surface and are designed to deliver the active drug across the skin, into the systemic circulation
Transdermal patches containing Desloratadine were prepared by the solvent casting method
The patches produced were found to be satisfactory in terms of physicochemical properties like appearance, thickness, weight variation, folding endurance, moisture content, tensile strength, percent elongation at break and percent drug content.The patch of F7 batch shows the maximum drug release in 24 hrs. the other batches.The F7 batch show the best physical appearance and folding appearance
Summary
Transdermal drug delivery systems are formulations that are applied to the body surface and are designed to deliver the active drug across the skin, into the systemic circulation. The impetus for the development of newer/novel drug delivery systems, apart from therapeutic efficacy is cost. Pharmacologic considerations including avoiding first pass effect and biotransformation may be important advantages of transdermal administration These advantages may be applied to the veterinary patient. The development of TDDS is multidisciplinary activity that encompasses fundamental feasibility studies starting from the selection of drug molecule to the demonstration of sufficient drug flux in an ex vivo and in vivo model followed by fabrication of a drug delivery system that meets all the stringent needs that are specific to the drug molecule (physicochemical and stability factors), the patient (comfort and cosmetic appeal), the manufacturer (scale up and manufacturability) and most important the economy.[2] The choice of drugs to be delivered transdermally is the most difficult one and careful consideration should be given to their selection. Desloratadine blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine.[3,4]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call